• Novavax earned $125 million on Oct. 29, 2026, as Sanofi initiated a Phase 3 influenza-COVID-19 combination vaccine trial in Europe.
• The trial assesses safety and immunogenicity of Nuvaxovid combined with Sanofi’s high-dose flu vaccine in adults aged 60 and older.
• The partnership has generated more than $1 billion in revenue to date.
• A further $75 million milestone is tied to successful completion of manufacturing technology transfer, anticipated in mid-2027.
• A U.S. combination vaccine launch following successful clinical and regulatory completion would trigger $225 million; combination products also carry royalties.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-120221), on October 29, 2026, and is solely responsible for the information contained therein.